Klinikum Chemnitz

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? (2020) Röllig C, Kramer M, Schliemann C, Mikesch JH, Steffen B, Krämer A, Noppeney R, et al. Journal article Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients (2020) Hack C, Häberle L, Brucker SY, Janni W, Volz B, Löhberg C, Hartkopf AD, et al. Journal article Nilotinib (NIL) vs. NIL Plus Pegylated Interferon alpha2B (IFN) Induction and NIL or IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1+Chronic Myeloid Leukemia (CML) Patients (PTS) in Chronic Phase (2020) Ernst T, Saussele S, Burchert A, Baerlocher GM, Bruemmendorf TH, La Rosee PG, Heim D, et al. Conference contribution Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial—PaCa-DD-041 (Eudra-CT 2009-011968-11) (2020) Zimmermann C, Distler M, Jentsch C, Blum S, Folprecht G, Zöphel K, Polster H, et al. Journal article EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia (2020) Stasik S, Middeke JM, Kramer M, Roellig C, Kraemer A, Scholl S, Hochhaus A, et al. Journal article Nilotinib Vs Nilotinib Plus Pegylated Interferon a (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response (2019) Hochhaus A, Burchert A, Saussele S, Baerlocher GM, Brummendorf TH, Rosee PL, Heim D, et al. Conference contribution Single cycle induction treatment with cisplatin/docetaxel plus durvalumab/tremelimumab in stage III-IVB head and neck squamous cell cancer (CheckRad-CD8 trial) (2019) Hecht M, Gostian AO, Eckstein M, Rutzner S, Von Der Gruen J, Illmer T, Hautmann MG, et al. Conference contribution A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA) (2019) Bischoff J, Barinoff J, Mundhenke C, Bauerschlag DO, Costa SD, Herr D, Luebbe K, et al. Journal article Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer (2019) Wunderle M, Pretscher J, Brucker SY, Volz B, Hartmann A, Fießler C, Hein A, et al. Journal article Clinical pharmacy services in Germany: A national survey (2019) Schulz C, Fischer A, Vogt W, Leichenberg K, Warnke U, Liekweg A, Georgi U, et al. Journal article